Finnrick, an independent testing programme, publishes 3 assays for Apextide Bio: 2 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 1 did not. Most recent assay 16 Jun 2026.
Apextide Bio registered as [object Object], listed by Finnrick as "Trading", has no storefront on record — Finnrick lists only a messaging or social contact. Source: Finnrick, https://www.finnrick.com/vendors/apextide-bio.
Listed in the Finnrick vendor directory. Not yet tested.
Apextide Bio is listed as active. Tracked by Finnrick. No test data available yet.
| Product | Assays | Result |
|---|---|---|
| Retatrutide | 3 | 2 passed, 1 failed |
Source: Finnrick, as published 2026-08-09. Pass and fail are Finnrick's classification against its own threshold, not ours.
| Status | Active |
|---|---|
| Vendor type | Research-use supplier |
These details were read from Apextide Bio's own website on 2026-08-19. Pages consulted:
Apextide Bio is listed as active and we hold 3 Finnrick assays (2 passing, 1 failing its purity threshold). That is evidence about the batches that were tested or published, not a guarantee about the vial you receive.
Yes. Finnrick, an independent testing programme, publishes 3 assays for Apextide Bio: 2 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 1 did not. Most recent assay 16 Jun 2026.
Popular peptides: Semaglutide, Tirzepatide, Retatrutide, BPC-157, CJC-1295, Ipamorelin.
Other reviewed vendors: Apollo Peptide Sciences Review, Apoxar Labs Peptides Review, Arailpharma.me Peptides Review.